Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer

The aim of this retrospective study was to assess the outcome of patients with metastasized castration-resistant early-onset prostate cancer refractory to chemotherapy receiving radioligand therapy with <sup>177</sup>Lutetium-PSMA-617 (LuPSMA-RLT). Twenty-five patients of ≤55 years of ag...

Full description

Bibliographic Details
Main Authors: Nicolai Mader, Daniel Groener, Nikolaos Tselis, Séverine Banek, James Nagarajah, Frank Grünwald, Amir Sabet
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
PSMA
<sup>177</sup>Lu-PSMA-617
early-onset prostate cancer
metastatic castration-resistant prostate cancer
younger
Online Access:https://www.mdpi.com/2072-6694/13/16/4193

Internet

https://www.mdpi.com/2072-6694/13/16/4193

Similar Items